Body Water Content in Cyanotic Congenital Heart Disease

Heart Defects, Congenital Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00000107
• Other study ID #: NCRR-M01RR00109-0737
• Secondary ID: M01RR000109
• Status: Completed
• Phase: N/A
• First received: January 18, 2000
• Last updated: June 23, 2005

Study information

• Verified date: December 2003
• Source: National Center for Research Resources (NCRR)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

Adults with cyanotic congenital heart disease have elevated levels of plasma proatrial natruretic peptide (proANP) which most likely results in chronic dehydration, leading to reduced oxygen transport to tissues and shortness of breath with activity. The purpose of this study is to characterize adults with cyanotic congenital heart defects with respect to their body composition (water and fat-free mass) and resting metabolic rates. The study consists of several measures of how much body water, fat and lean tissue a subject has, and measures the number of calories the subject's body uses at rest. Adult subjects with cyanotic congenital heart disease will be recruited along with healthy noncyanotic control subjects matched for age, gender, and body weight.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 17 Years to 60 Years

Eligibility

Inclusion Criteria:

• Resting blood pressure below 140/90

Study Design

Observational Model: Case Control

Related Conditions & MeSH terms

• Congenital Abnormalities
• Heart Defects, Congenital

Locations

Country	Name	City	State
United States	University of Vermont	Burlington	Vermont

Sponsors (1)

Lead Sponsor	Collaborator
National Center for Research Resources (NCRR)

Country where clinical trial is conducted

United States,